|Mr. Jason Ryan||Exec. Chair of the Board||30k||N/A||1974|
|Mr. Isaac Ro||Consultant||541.99k||N/A||N/A|
|Ms. Katherine A. Stueland||CEO & Director||N/A||N/A||1976|
|Mr. Kevin Feeley||Sr. VP of Operations & CFO||N/A||N/A||N/A|
|Mr. Robert Sebra Ph.D.||VP of Technology Devel.||N/A||N/A||N/A|
|Dr. Matthew Davis Ph.D.||Chief Technology & Product Officer||N/A||N/A||N/A|
|Dr. Gustavo Stolovitzky Ph.D.||Chief Science Officer||N/A||N/A||N/A|
|Mr. Murali Mani||Chief Compliance & Privacy Officer||N/A||N/A||N/A|
|Mr. Joel Harrison Kaufman||VP of Fin. & Corp. Devel.||N/A||N/A||1989|
|Ms. Karen White||Chief People Officer||N/A||N/A||1971|
Sema4 Holdings Corp., doing business as Sema4, operates as a health information company that enhances diagnosis, treatment, and prevention of disease through data. The company provides Centrellis, an AI-driven health intelligence platform that delivers comprehensive insights to biopharma to accelerate the drug discovery, development, and commercialization life-cycle, as well as analytics for actionable insights, pre-clinical and clinical trial support, and advanced sequencing services. It also offers Sema4 Signal that enables and advances precision oncology care, from prevention to treatment to remission; and testing for carrier screening, noninvasive prenatal testing, and newborn screening, as well as hereditary cancer testing. In addition, the company provides COVID-19 testing solutions. Sema4 Holdings Corp. was incorporated in 2020 and is headquartered in Stamford, Connecticut.
Sema4 Holdings Corp.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.